LindaC.HoMD

Hematopathology, Anatomic Pathology, Clinical Pathology

Medical Director, Hematology Oncology Clinical Development

Dr. Ho is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Linda Ho is a Pathologist based in Bothell, WA, with subspecialties in Hematopathology and Genitourinary Pathology. She completed a residency in Anatomic and Clinical Pathology at McGaw Medical Center of Northwestern University, and fellowships in Hematopathology and Genitourinary Pathology at Case Western Reserve University/University Hospitals Case Medical Center. She holds a medical degree from Loyola University Chicago Stritch School of Medicine and BA degrees in Medical Anthropology and Biology from Case Western Reserve University. Dr. Ho is currently the Medical Director at AbbVie Oncology and has previous experience at Pfizer Oncology, Seattle Genetics, and AbbVie. She is experienced in hematopathology, hematologic malignancies, drug development, and medical oncology. Her research has been published in notable journals and includes studies on brentuximab vedotin in classical Hodgkin lymphoma and diffuse large B-cell lymphoma.

Case Western Reserve University/University Hospitals Cleveland Medical Center Surgical PathologyFellowship, Selective Pathology, 2009 - 2010
Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematopathology, 2008 - 2009
McGaw Medical Center of Northwestern UniversityResidency, Pathology-Anatomic and Clinical, 2003 - 2008
Loyola University Chicago Stritch School of MedicineClass of 2003
Case Western Reserve University BA, Medical Anthropology and Biology, magna cum laude, 1994 - 1998

PubMed

Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.
Nancy L Bartlett, Uwe Hahn, Won-Seog Kim, Isabelle Fleury, Kamel Laribi
Journal of Clinical Oncology. 2025-03-20
1 citations
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma.
Hun Ju Lee, Rod Ramchandren, Judah Friedman, Jason Melear, Ian W Flinn
Blood. 2025-01-16
123 citations
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
Ranjana H. Advani, Alison J. Moskowitz, Nancy L. Bartlett, Julie M. Vose, Radhakrishnan Ramchandren
Blood. 2021-08-12

Abstracts/Posters

Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above
Christopher A. Yasenchak, MD , Rodolfo Bordoni, MD , Victor Yazbeck, MD , Dipti Patel-Donnelly, MD , Timothy Larson, MD , Trevor Newhook, MS , Linda Ho , Matthew..., American Society of Hematology, Orlando, FL, 11/13/2019
Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years
Christopher A. Yasenchak, MD , Rodolfo Bordoni, MD , Victor Yazbeck, MD , Dipti Patel-Donnelly, MD , Thomas Anderson , Timothy Larson, MD , Trevor Newhook, MS , ..., American Society of Hematology, Orlando, FL, 11/13/2019
Brentuximab Vedotin in Combination with Nivolumab, Doxorubucin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma
Judah Friedman, MD , Hun Ju Lee, MD , Linda Ho , Ian W. Flinn, MD PhD, American Society of Hematology, Orlando, FL, 11/13/2019